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Abstract
Background: Cough is one of the most frequent symptoms in children and is the most common symptom for
which children visit a health care provider.
Methods: This is an observational study on acute cough associated with upper respiratory tract infection (URTI) in
children. The study evaluates the epidemiology and impact of cough on quality of sleep and children’s activities,
and the outcome of cough with antitussive treatments in pediatric routine clinical practice. Study assessments
were performed through a pediatric cough questionnaire (PCQ), developed by the Italian Society of Cough Study.
A total of 433 children visited by family care pediatricians for acute cough due to a URTI were enrolled in this
study, with mean age of 6.1 years (SD 3.6). Cough type, duration, severity and frequency, cough impact on sleep
disturbances of children and parents and on school and sport activities were assessed at baseline. In a subset of
241 children who were either treated with antitussive drugs (levodropropizine n = 101, central antitussives n = 60)
or received no treatment (n = 80), the outcome of cough after 6 days was analyzed in terms of resolution,
improvement, no change, or worsening. Descriptive analysis, c
2 test, and multivariate analysis with stepwise logistic
regression were performed.
Results: Cough disturbed sleep in 88% of children and 72% of parents. In children treated with cough
suppressants, the duration, type, intensity, and frequency cough were similar at baseline in the two groups
respectively treated with levodropropizine and central antitussives (cloperastine and codeine). Both
levodropropizine and central drugs reduced cough intensity and frequency. However, percentage of cough
resolution was higher with levodropropizine than with central antitussives (47% vs. 28% respectively, p = 0.0012).
Conclusions: Acute cough disturbs sleep in most children and their parents. Both levodropropizine and central
antitussives reduced cough intensity, with levodropropizine producing a higher cough resolution rate.
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Background
Cough is one of the most frequent symptoms in chil-
dren [1,2] and is one of the most common reasons for
which parents seek medical attention for their child [3].
In most children, acute cough is due to viral upper
respiratory tract infection (URTI), i.e., the common cold
[4]. It is recognized that preschool and school children
might suffer from acute respiratory infections 6 to 8
times a school year and can cough 140 coughs daily
with a URTI [5].
Cough resulting from URTI may be a distressing
symptom, and empiric treatment with antitussive agents
is often used [6]. Among antitussive drugs available for
the treatment of cough in children, codeine and cloper-
astine are centrally acting agents (opioids and non
opioids) that are believed to inhibit cough primarily by
their effect on the cough center, while levodropropizine
is a non-opioid agent whose suggested peripheral
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cough reflex at the peripheral nerve level (sensory C-
fibres) [7] with possible modulation of sensory neuro-
peptide levels within the respiratory tract [8].
The aim of this study was to evaluate the epidemiol-
ogy of acute cough associated with URTI in children,
the impact of acute cough on quality of sleep of children
and their parents, the impact of acute cough on chil-
dren’s sport and school activities, and acute cough out-
come with antitussive treatments.
Methods
This is an observational study on pediatricians’ routine
clinical practice, including all children who presented to
the offices of four family care pediatricians due to acute
cough (i.e., onset ≤ 3 weeks) associated with a URTI
from 1st February 2010 to 30th April 2010. Study
assessments were performed through a specific pediatric
cough questionnaire (PCQ), developed and approved by
the Scientific Committee of the Italian Society of Cough
Study (see Appendix). Baseline assessment was per-
formed during the first study visit by the pediatrician,
who interviewed parents and/or patients and compiled
the first part of the PCQ, addressing the evaluation of
type, duration, frequency and severity of cough, sleep
disturbances of both children and parents (quality of
sleep), and impact of cough on school activities and
sports/games. Pediatricians were free to prescribe the
most appropriate treatments for cough based on their
clinical practice experience. The PCQ was given to the
children’s parents for self assessment to be performed
after 6 days from the first study visit, compiling the sec-
ond part of the questionnaire reporting actually admi-
nistered treatments, and the outcome of cough in terms
of resolution, improvement, no change, or worsening.
Patients were revisited after one week from the first
visit, and questionnaires were collected by the physician,
as well as any adverse events experienced by the child.
Statistics
Continuous data are presented as mean +/- standard
deviation. Categorical and discrete data are presented as
frequency and percentages. Differences between groups
were tested using the c
2 test for categorical and discrete
variables. A multivariate analysis was performed. Using a
stepwise logistic regression we assessed how changes in
cough severity related to the age of children, the presence
of concomitant respiratory diseases, the type of cough,
the use of antibiotics, and the antitussive therapy used.
Results
Epidemiology of Cough
The total number of children enrolled in this study
was 433. The mean age of children was 6.1 years (SD
3.6 - median 5.2 years). The youngest enrolled was 1
month, while the oldest was 14 years (Figure 1).
Clinical findings
Clinical data including type, duration, frequency and
severity of cough were recorded on the PCQ at the first
study visit. In 88 (20.3%) patients a concomitant illness
was found. Allergies were the most frequent conditions
with an incidence of 9% (Table 1).
Frequency and intensity of cough were mostly
reported as frequent and moderate, respectively
(Table 2).
Quality of sleep, sport and school activities
The PCQ evaluated the impact of cough on quality of
sleep in children and their parents through four ques-
tions (Figure 2):
To what extent did cough symptoms disturb children’s
sleep?
To what extent did children’s cough symptoms disturb
their parent’s sleep?
To what extent did children’s cough symptoms inter-
fere in their scholastic activities?
To what extent did children’s cough symptom inter-
fere with sport activities?
Regarding pre-scholar children and infants, scholastic
activities were to be intended as activities at kindergar-
ten/nursery/crèche, while sport activities were to be
intended as games.
Figure 1 Age of enrolled children.
Table 1 Concomitant Respiratory Illnesses
Concomitant respiratory illnesses 20.3%
Allergies 9.0%
Asthma 6.2%
Bronchitis 3.0%
Rhinitis/Sinusitis 1.6%
Tonsillitis 0.5%
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Of the total 433 patients, 80 received no treatment for
cough since the doctor did not prescribe any medica-
tion, while 161 were treated with cough suppressant
agents, which were the main drugs used in this study.
Of these, 101 children received levodropropizine and 60
patients were treated with central antitussives (51 with
cloperastine, and 9 with codeine).
The outcome of cough after 6 days was analyzed in
terms of resolution, improvement, no change, or wor-
sening in this subset of 241 children who were treated
with antitussive drugs or received no treatment.
Regarding patients’ characteristics at baseline (Table
3), the two groups respectively treated with levodropro-
pizine and central antitussives (cloperastine and
codeine) were similar for cough duration (number of
days since cough onset), cough type, intensity, and fre-
quency. Average age of patients treated with central
antitussives was approximately 1 year and a half higher
than patients who received levodropropizine, and this
appears to be consistent with current routine clinical
practice in the pediatric population, considering that
codeine is contraindicated in children below 2 years. As
expected in a real life observational study in which ther-
apeutic decisions were driven by physicians’ opinions
based on their clinical practice experience, cough inten-
sity and frequency were significantly lower in the group
of patients for which pediatricians decided not to pre-
scribe any treatment than in the two groups treated
with levodropropizine and central antitussives,
respectively.
Correlation between treatment outcome and type of
treatment received
There was a significant difference in treatment out-
comes between the groups receiving levodropropizine
and those receiving central antitussives. The percentage
of children reporting cough resolution was significantly
higher with levodropropizine than with central antitus-
sives (47% vs. 28% respectively, p = 0.0012), and no
change/worsening was reported in 3% receiving levodro-
propizine vs. 18% for central antitussives (Figure 3).
Twenty per cent of patients receiving no therapy
reported resolution of cough, while 55% reported
improvement of their symptoms.
Correlation between intensity of cough and treatment
outcomes
Moderate cough
Levodropropizine showed better treatment results than
central antitussives and no therapy. A statistically signif-
icant difference was found (p < 0.05) in terms of percen-
tage of cough resolution. Only 3% of patients in the
levodropropizine group reported no change or worsen-
ing of cough symptoms vs. 22% and 37% for central
antitussives and no therapy, respectively (Figure 4).
Severe Cough
No patients who received levodropropizine reported no
change/worsened cough (Figure 5).
Multivariate Analysis (Step-wise Logistic Regression)
A multivariate analysis by stepwise logistic regression
was done to evaluate the probability of cough improve-
ment related to clinical characteristics. The independent
variable was resolution or improvement of cough while
covariates were: age (continuous - months), concomitant
diseases (Yes vs. No), type of cough (productive, dry, or
mixed), association with antibiotics (Yes vs. No), antitus-
sive therapy (levodropropizine, central antitussive, or
none). The coefficients values derived from the logistic
regression are shown in Table 4.
Cough resolution or improvement was most strongly
associated with the type of antitussive used and type of
cough. Children with productive cough tended to respond
better than patients with mixed cough. Cough outcome
was better with levodropropizine than with central antitus-
sives. No statistically significant correlation was found with
age, concomitant diseases or use of antibiotics.
Discussion
Of the 433 children enrolled in this observational study,
52% were preschool ( < 6 years). The mean age of
Table 2 Intensity and Frequency of cough
Intensity of Cough Total
Mild 81 (18.7%)
Moderate 237 (54.7%)
Severe 115 (26.6%)
Total 433 (100%)
Frequency of Cough Total
Occasional 126 (29.1%)
Frequent 258 (59.6%)
Continuous 49 (11.3%)
Total 433 (100%)
Figure 2 Quality of sleep, sport and school activities.
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due to URTI disturbed the children’s quality of sleep,
and the scholastic and sport activities were affected in
76% and 61% of children, respectively. The quality of
parent’s sleep was affected in 72% in parents
In the subset of 241 children who were treated with
antitussive drugs (levodropropizine or central antitus-
sives, n = 161) or received no treatment (n = 80), 80%
were reported to have moderate or severe cough. More
children were treated with levodropropizine (n = 101)
than with central cough suppressants (codeine and clo-
perastine, n = 60). All antitussive drugs reduced cough
intensity and frequency. However, cough resolution was
significantly higher with levodropropizine than with cen-
tral antitussives (47% vs. 28% respectively, p = 0.0012).
T h er e s u l t so fal o g i s t i ca n a l y s i ss u g g e s tt h a tt h eu s eo f
antibiotics had no significant correlation with cough
improvement. Multivariate analysis showed a statistically
significant difference of cough improvement with levo-
dropropizine vs. central antitussives or no therapy, inde-
pendent of antibiotic use or concomitant illnesses.
In conclusion, cough significantly disturbed children’s
and parents’ sleep and daily activities. Levodropropizine
w a st h ea n t i t u s s i v ed r u gm o s tc o m m o n l yu s e db yt h e
Table 3 Patients Characteristics at Baseline
Levodropropizine
(LDP) n = 101
Central Antitussives (CA) n =
60
No Treatment (NT) n =
80
p
* p < 0,05 LDP. vs
CA
Age (years), mean (min-max) 5.9* (0.8-14.8) 7.3 (1.6-13.3) 6.3 (0.3-14.0) NS LDP vs NT
NS CA vs NT
Cough Duration (days), mean (min-
max)
4.6 (2-15) 5.8 (2-21) 4.7 (2-17) NS
Cough Type (%)
Productive 36.6% 25.0% 46.3% NS
Dry 50.5% 63.3% 40.0% NS
Mix 12.9% 11.7% 13.8% NS
Cough Intensity (%)
Mild 7.9% 8.3% 42.5%* *p < 0.01 NT vs LDP/
CA
Moderate 58.4% 53.3% 51.3% NS
Severe 33.7% 38.3% 6.3%* *p < 0.01 NT vs LDP/
CA
Cough Frequency (%)
Occasional 18.8% 10.0% 60.0% NS
Frequent 65.3% 75.0% 36.3% NS
Continuous 15.8% 15.0% 3.8%* *p < 0.01 NT vs LDP/
CA
Figure 3 Treatments outcomes. Chi sq. (2 DF) = 13,4121, p = 0,0012
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of resolution and improvement appeared to be better
with levodropropizine than with centrally acting antitus-
sives (cloperastine and codeine).
Further large randomized clinical trial in children
should be conducted in order to confirm the efficacy of
antitussive drugs used in this observational study.
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Figure 5 Treatments outcomes - Severe cough.
Figure 4 Treatments outcomes - Moderate cough.
Table 4 Logistic analysis
COVARIATES Contrast Coeff. SE p
Age (months) Continuous -0.003 0.0033 0.311
Concomitant diseases Yes vs. No 0.584 0.4020 0.147
Productive cough vs. dry -0.144 0.3200 0.652
vs. mixed -1.037 0.4010 *0.010
Association with antibiotics
Yes
vs. No 0.471 0.3440 0.172
Levodropropizine vs. Central
antitussives
-2.026 0.6820 *0.003
vs. No Treatment -2.181 0.6750 *0.001
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